SLC5A2 and kidney disorder: Similar to the results reported in the EMPA-REG OUTCOME [17] and CANVAS [18] trials, SGLT2 inhibitors demonstrated significant reductions in heart failure hospitalization and renal disease progression across the included studies, with dapagliflozin showing a particularly robust effect in patients with heart failure and reduced ejection fraction (DAPA-HF).